Risankizumab Versus Secukinumab: A Real-World Efficacy and Cost per Responder Comparison in Patients With Psoriasis in Italy

Risankizumab Versus Secukinumab: A Real-World Efficacy and Cost per Responder Comparison in Patients With Psoriasis in Italy

Introduction: Risankizumab and secukinumab are effective treatment options for patients with moderate to severe psoriasis. Objective: We sought to estimate the efficacy and the cost per responder of risankizumab and secukinumab by comparing these two drugs in a real-life setting. Methods:.A mul...

Full description

Saved in:
Bibliographic Details
Main Authors: Federico Pirro, Giacomo Caldarola, Nicoletta Bernardini, Maria Grazia Celeste, Annunziata Dattola, Eleonora De Luca, Marco Galluzzo, Domenico Giordano, Chiara Izzi, Giulia Maretti, Lorenzo Marcelli, Roberto Ravasio, Antonio Giovanni Richetta, Nevena Skroza, Marina Talamonti, Arianna Zangrilli, Luca Bianchi, Giovanni Pellacani, Severino Persechino, Concetta Potenza, Ketty Peris, Clara De Simone
Format: Article
Language:English
Published: Mattioli1885 2025-01-01
Series:Dermatology Practical & Conceptual
Subjects:
efficacy
cost per responder
risankizumab
secukinumab
psoriasis
Online Access:https://dpcj.org/index.php/dpc/article/view/4838
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://dpcj.org/index.php/dpc/article/view/4838

Similar Items